Report : Europe Biodefense Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Anthrax, Small pox, Botulism, Radiation/Nuclear, Others), and Geography
The Anthrax Segment by Product is expected to grow at A Fast Pace over the Forecast Period
According to The Insight Partners market research study of 'Europe Biodefense Forecast to 2027 - Covid-19 Impact and Regional Analysis by Product' The Europe Biodefense market is expected to reach US$ 2,516.91 Mn in 2027 from 1,286.58 Mn in 2019. The market is estimated to grow with a CAGR of 8.8% from 2020-2027. The report provides trends prevailing in the Europe Biodefense market and the factors driving market along with those that act as hindrances.
The Europe Biodefense market, based on the product, is segmented into Anthrax, Small pox, Botulism, and Radiation/Nuclear. The Anthrax segment held the largest share of the market in 2019 and also estimated to register the highest CAGR in the market during the forecast period owing to increasing funding by the governments of other countries to develop and stockpile adequate vaccines against anthrax mainly through a variety of initiatives, such as BioWeapons Prevention Project (BWPP), British American Security Information Council (BASIC), and the Joint Program Executive Office for Chemical & Biological Defense.
The Europe Biodefense market is expected to grow, owing to the presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. However, fluctuations in funding due to changing EU is expected to restraint the growth of the market during the forecast years.
Leading companies operating in the Europe Biodefense market are as Bavarian Nordic, Alnylam Pharmaceuticals, Inc., SIGA Technologies, Emergent BioSolutions Inc., and Cleveland Bio Labs among others.
The report segments Europe Biodefense market as follows:
Europe Biodefense Market– By Geography